Working with TipRanks
Follow Us
Stocks
ETFs
Options
Crypto
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Knight Therapeutics (KHTRF)
OTHER OTC:KHTRF
RESEARCH TOOLSreports
Knight Therapeutics (KHTRF) Stock Price & Analysis
31 Followers
KHTRF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.15 - $4.24
Previous Close$3.85
Volume100.00
Average Volume (3M)9.44K
Market Cap
$398.19M
Enterprise Value$360.56M
Total Cash (Recent Filing)C$130.50M
Total Debt (Recent Filing)C$79.20M
Price to Earnings (P/E)-83.9
Beta0.51
Next Earnings
Mar 21, 2024Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding104,360,736
10 Day Avg. Volume2,920
30 Day Avg. Volume9,436
Standard Deviation0.07
R-Squared0.25
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.37
Price to Sales (P/S)4.50
Price to Cash Flow (P/CF)-92.50
P/FCF Ratio101.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.63Price Target Upside20.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Knight Therapeutics News
Press ReleasesKnight Therapeutics Reports Third Quarter 2023 Results
Pre-EarningsIs KHTRF a Buy, Before Earnings?
Ownership Overview
85.55% Insiders
1.89% Mutual Funds
0.67% Other Institutional Investors
11.88% Public Companies and
Individual Investors
KHTRF FAQ
What was Knight Therapeutics’s price range in the past 12 months?
Knight Therapeutics lowest stock price was $3.15 and its highest was $4.24 in the past 12 months.
What is Knight Therapeutics’s market cap?
Currently, no data Available
When is Knight Therapeutics’s upcoming earnings report date?
Knight Therapeutics’s upcoming earnings report date is Mar 21, 2024 which is in 109 days.
How were Knight Therapeutics’s earnings last quarter?
Knight Therapeutics released its earnings results on Nov 09, 2023. The company reported $0.066 earnings per share for the quarter, beating the consensus estimate of -$0.023 by $0.089.
Is Knight Therapeutics overvalued?
According to Wall Street analysts Knight Therapeutics’s price is currently Undervalued.
Does Knight Therapeutics pay dividends?
Knight Therapeutics does not currently pay dividends.
What is Knight Therapeutics’s EPS estimate?
Knight Therapeutics’s EPS estimate is $0.
How many shares outstanding does Knight Therapeutics have?
Knight Therapeutics has 104,360,730 shares outstanding.
What happened to Knight Therapeutics’s price movement after its last earnings report?
Knight Therapeutics reported an EPS of $0.066 in its last earnings report, beating expectations of -$0.023. Following the earnings report the stock price went up 2.89%.
Which hedge fund is a major shareholder of Knight Therapeutics?
Currently, no hedge funds are holding shares in KHTRF
---
Knight Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.63 (20.26% Upside)
$4.63 (20.26% Upside)
Insider Transactions
Bought Shares
Worth $745.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.62%
12-Months-Change
Fundamentals
Return on Equity
-0.91%
Trailing 12-Months
Asset Growth
-0.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Knight Therapeutics
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.
---
---